Rhythm secures $350M LG Chem deal plus $750M loan
Alpha Vantage · Quantisnow · · AI-summarised by FinFlash
Rhythm Pharmaceuticals has amended its exclusive license agreement with LG Chem for bivamelagon, securing fixed payments of $350 million over four years and a 1% royalty. This agreement coincides with Rhythm Pharmaceuticals obtaining a $750 million term loan from KKR and Blackstone. The news highlights a significant financial restructuring and partnership update for the biotechnology company.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.